Loading…
Loading…
The moves that matter — curated from across forex, stocks and crypto, and readable in full right here.
Updated 30 Jun, 11:00 pm
Affirm Holdings (NASDAQ:AFRM) Stock Analysis: Analyst Ratings and Market Performance Piper Sandler initiated coverage on Affirm Holdings (NASDAQ:AFRM) with an Overweight rating and a $103.00 price target , indicating a positive investment outlook. The company's shares have demons
Despite an analyst downgrade from HSBC, Fortinet (NASDAQ: FTNT) stock demonstrated strong market resilience, closing at $155.42 and reaching a new 52-week high of $159.04 . The company is strategically expanding its product portfolio, including new FortiGate G Series models with
AeroVironment (NASDAQ: AVAV) exceeded analyst expectations with strong quarterly earnings per share (EPS) of $1.84 and robust revenue of $641.62 million . The company experienced substantial growth, with revenue more than doubling year-over-year and its stock price increasing by
FactSet Research Systems Inc. (NYSE:FDS) is projected to report strong third-quarter earnings with an estimated EPS of $4.44 and revenue of $617.91 million , reflecting year-over-year growth. The company's growth is bolstered by robust regional performance in the Americas and Asi
Analyst firm Piper Sandler reduced its price target for PayPal, maintaining a Neutral rating due to cautious sentiment. PayPal is facing significant growth challenges, with slowing revenue growth and modest daily active user increases, contributing to a substantial stock decline
Mixed Insider Activity: While the CFO sold shares, a director made significant open-market purchases, suggesting differing internal views or strategic moves within the company. Post-Earnings Buying Signals Confidence: A director's substantial share purchases followed a Q2 earning
Clinical Trial Impact: Biotech stock valuations, exemplified by Evommune, Inc. (NASDAQ: EVMN) , are highly susceptible to clinical trial results. Company-Specific News: Significant stock declines can be triggered by specific company announcements or developments, as seen with Fre
Acquisitions and successful financing are major catalysts for significant stock price increases. Leadership appointments can positively influence investor confidence and company valuation. Leveraged ETFs can amplify returns during broader market rallies, reflecting wider market t
Strong Analyst Sentiment : Merck & Co., Inc. (NYSE: MRK) holds an average brokerage recommendation of 1.73 , indicating a "Strong Buy" to "Buy" rating for the pharmaceutical stock. Increased Price Target : Scotiabank raised its price target for Merck to $155 , signaling increased
The consensus price target for Nike has significantly decreased over the past year, reflecting adjusted expectations due to recent performance and market conditions. Analysts project a notable decline in Nike's Q4 revenue, operating income, and EPS, indicating potential headwinds
Wedbush analyst Laura Chico has increased her price target for Viridian Therapeutics to $43 , signaling strong confidence in the biopharmaceutical company's future. The U.S. Food and Drug Administration (FDA) has approved Viridian Therapeutics' new drug, Lumvoa, for Thyroid Eye D
Scotiabank raised its price target for Merck to $155.00 from $136.00 , maintaining an "Outperform" rating. The wider analyst community, including Zacks Investment Research, gives Merck an average brokerage recommendation of 1.73 , indicating a strong "Buy" consensus. Merck's stoc
Analyst Jeff Van Rhee of Craig-Hallum has raised the price target for Rocket Lab (NASDAQ: RKLB) to $120.00 , signaling strong confidence in the company's future. Rocket Lab is set to acquire Iridium Communications (NASDAQ: IRDM) in an approximately $8.00 billion cash-and-stock de
Earnings Growth Expected: Analysts project an increase in earnings per share and revenue for Progress Software's upcoming quarterly report. Positive Stock Momentum: The company's shares have shown recent strength, with a notable 11.2% surge in a recent trading session. Financial
Deutsche Bank's Positive Outlook: The bank reiterated a "Buy" rating for UBS, raising its price target to CHF 45 . Strategic U.S. Wealth Management Expansion: UBS is growing its presence in the U.S. by adding new financial advisor teams managing over $2.00 billion in assets. Evol
Mobile-health Network Solutions (NASDAQ: MNDR) executed a one-for-six reverse stock split on June 29, 2026, to increase its share price and maintain its Nasdaq listing. The reverse split reduced outstanding Class A Ordinary Shares from approximately 5.33 million to about 888,592
Jefferies increased its price target for Life Time Group to $51.00 , suggesting a 24.9% potential upside. Life Time Group shares have gained 31.2% year-to-date, significantly outperforming the broader Zacks Consumer Discretionary sector. The company consistently beats earnings es
Iridium Communications (NASDAQ:IRDM) received a "Perform" rating downgrade from Oppenheimer, shifting from "Outperform," following its acquisition by Rocket Lab. Rocket Lab is acquiring Iridium Communications in a significant cash-and-stock deal valued at approximately $8 billion
Headlines provided by Investing.com